Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Cytotoxic Effect
100%
Gastric Cancer
100%
Antitumoral Effect
100%
CD44 Variant 6
100%
Primary T Cells
20%
Monoclonal Antibody
13%
Tumor Progression
13%
ScFv
13%
Gastric Cancer Cell Lines
13%
T-ratio
13%
Flow Cytometry
6%
Radiotherapy
6%
Expression Level
6%
Poor Prognosis
6%
Metastasis
6%
Fluorescence Microscopy
6%
Cell Tumor
6%
High Affinity
6%
5-year Survival
6%
Plasmid
6%
Cell Killing
6%
Cancer Types
6%
Recombinant
6%
Apoptosis Resistance
6%
Overall Survival Rate
6%
T Cell Activation Markers
6%
Recurrent Tumor
6%
Surface Expression
6%
Specific Binding
6%
Recombinant Protein
6%
Cancer Cases
6%
Targeted Therapy
6%
Antigen Expression
6%
Cluster of Differentiation 44 (CD44)
6%
Transduction Efficiency
6%
Cytotoxic Activity
6%
Effector Memory
6%
Memory Phenotype
6%
Jurkat T Cells
6%
Jurkat Cells
6%
Antibody-drug Conjugate
6%
Activity Effect
6%
Promising Target
6%
T Cell Lines
6%
In Vivo Experiment
6%
Off-target Effects
6%
Jurkat Cell Line
6%
Lentivirus
6%
T Cell Exhaustion
6%
NSG Mice
6%
Antigen Exposure
6%
CD69
6%
Gastric Cancer Cells
6%
Chimeric Antigen Receptor T-cell Therapy
6%
CD69 Expression
6%
Killing Assay
6%
MKN45
6%
Bioluminescence Microscopy
6%
Immunology and Microbiology
Chimeric Antigen Receptor
100%
CD44v6 Antigen
100%
T Cell
26%
Monoclonal Antibody
13%
Chimeric Antigen Receptor T-Cell
13%
Gastric Cancer Cell Line
13%
CD69
13%
Bivatuzumab
13%
Cancer Cell
6%
Cell Line
6%
Survival Rate
6%
Programmed Cell Death
6%
Cytotoxicity
6%
Cell Killing
6%
Bioluminescence
6%
Plasmid
6%
T Cell Activation
6%
Target Cell
6%
CD44
6%
Antigen Expression
6%
Fluorescence Microscopy
6%
Overall Survival
6%
Lentivirus
6%
NSG Mouse
6%
Chimeric Antigen Receptor T-Cell Therapy
6%
Antibody Drug Conjugate
6%
In Vitro
6%
T Cell Exhaustion
6%
Jurkat Cell Line
6%